SNOA
Sonoma Pharmaceuticals, Inc.
$1.07
+5.94%
$1.8M
No data for this timeframe.
Vol
Market Cap$1.8M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$68.8K
Inst. Activity1 buys / 2 sells
SEC Reports3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001367083·Prev Close $1.01
Recent Activity
Apr 30, 2026
short_interest
FTD: SNOA — 903,191 shares ($1.0M) failed to deliver
Settlement: 20260430, Price: $1.06, FTD Value: $957,382.46, SONOMA PHARMACEUTICALS INC COM
Apr 27, 2026
SEC
Sonoma Pharmaceuticals priced a $4 million public offering of 2,962,962 units, each consisting of one share of common st
424B4 — Impact 6/10
Apr 17, 2026
SEC
Sonoma Pharmaceuticals is conducting a $5 million public offering of units, each consisting of one share of common stock
S-1 — Impact 5/10
Apr 9, 2026
SEC
Sonoma Pharmaceuticals (SNOA) entered into a manufacturing and supply agreement with Kenvue Brands LLC to produce Microc
8-K — Impact 4/10
Inst.
VANGUARD GROUP INC — NEW
20,873 shares ($81.0K)
Inst.
UBS Group AG — NEAR_EXIT
108 shares ($419.00)
Price Targets
Historical data — last covering-analyst action Sep 2023. No current recommendation available.
$12.00 (Sep 2023)
Current $1.07
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 5, 2023 | Ladenburg Thalmann | INITIATE | Buy |
| Mar 6, 2018 | Maxim Group | DOWNGRADE | Buy → Hold |
| Dec 28, 2017 | Benchmark | INITIATE | Speculative Buy |
| Nov 10, 2017 | Maxim Group | MAINTAIN | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 | $-0.24 — $-0.24 | 1 | |
| Current FY | $-1.61 | $-1.61 — $-1.61 | 1 | |
| Next FY | $-0.56 | $-0.56 — $-0.56 | 65% YoY | 1 |
Latest Reports
BEARISH
424B4
6/10
Sonoma Pharmaceuticals priced a $4 million public offering of 2,962,962 units, each consisting of one share of common st
Apr 27, 2026
NEUTRAL
S-1
5/10
Sonoma Pharmaceuticals is conducting a $5 million public offering of units, each consisting of one share of common stock
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $68.7K | NEW |
| BANK OF AMERICA CORP | $65.00 | — |
| MORGAN STANLEY | $15.00 | — |
3 institutional holders with $68.8K total value (18,909 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 18,887 | $68.7K | 99.9% | NEW |
| 2 | BANK OF AMERICA CORP /DE/ | 18 | $65.00 | 0.1% | — |
| 3 | MORGAN STANLEY | 4 | $15.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 20,873 | — | $81.0K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 14,417 | 108 | -99.3% | $419.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 17,800 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 17,800 | — | $50.6K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,852 | 14,417 | +678.5% | $41.0K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 17,430 | 1,852 | -89.4% | $4.1K | 2025-Q1 |
| UBS Group AG | ADD | 12,730 | 17,430 | +36.9% | $46.9K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
BEARISH
424B4
6/10
Sonoma Pharmaceuticals priced a $4 million public offering of 2,962,962 units, each consisting of on
Apr 27, 2026
NEUTRAL
S-1
5/10
Sonoma Pharmaceuticals is conducting a $5 million public offering of units, each consisting of one s
Apr 17, 2026
NEUTRAL
8-K
4/10
Sonoma Pharmaceuticals (SNOA) entered into a manufacturing and supply agreement with Kenvue Brands L
Apr 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2023): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2023. No current recommendation available.
$12.00 mean target (Sep 2023)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.07 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.24 | $-0.24 | $-0.24 | — | — | — | $0.0B | — | 1 |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-03-31 |
$-1.61 | $-1.61 | $-1.61 | — | — | 1↑ 0↓ | $0.0B | — | 1 |
| Next FY 2027-03-31 |
$-0.56 | $-0.56 | $-0.56 | 65.2% | — | 1↑ 0↓ | $0.0B | 15.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.240 | |
| 7d ago | $0.000 | -0.240 |
| 30d ago | $0.000 | -0.240 |
| 60d ago | $0.000 | -0.240 |
| 90d ago | $0.000 | -0.240 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 5, 2023 | Ladenburg Thalmann | INITIATE | — | Buy |
| Mar 6, 2018 | Maxim Group | DOWNGRADE | Buy | Hold |
| Dec 28, 2017 | Benchmark | INITIATE | — | Speculative Buy |
| Nov 10, 2017 | Maxim Group | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 30, 2026
short_interest
FTD: SNOA — 903,191 shares ($1.0M) failed to deliver
Settlement: 20260430, Price: $1.06, FTD Value: $957,382.46, SONOMA PHARMACEUTICALS INC COM
Apr 29, 2026
short_interest
FTD: SNOA — 840,284 shares ($0.9M) failed to deliver
Settlement: 20260429, Price: $1.04, FTD Value: $873,895.36, SONOMA PHARMACEUTICALS INC COM
Apr 28, 2026
short_interest
FTD: SNOA — 830,856 shares ($0.9M) failed to deliver
Settlement: 20260428, Price: $1.11, FTD Value: $922,250.16, SONOMA PHARMACEUTICALS INC COM
Apr 27, 2026
short_interest
FTD: SNOA — 861,629 shares ($1.0M) failed to deliver
Settlement: 20260427, Price: $1.14, FTD Value: $982,257.06, SONOMA PHARMACEUTICALS INC COM